{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:38:18Z","timestamp":1792597098718,"version":"4.5.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012524","name":"American Lebanese Syrian Associated Charities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012524","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Laboratory Medicine"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.cll.2026.07.007","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:56:31Z","timestamp":1786996591000},"page":"717-731","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Role of Therapeutic Drug Monitoring in the Treatment of Childhood Leukemia"],"prefix":"10.1016","volume":"46","author":[{"given":"Milre M.","family":"Matherne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope D.","family":"Swanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Brooke","family":"Bernhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro R.","family":"Molinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.cll.2026.07.007_bib1","doi-asserted-by":"crossref","first-page":"863","DOI":"10.4155\/bio.10.48","article-title":"Therapeutic drug monitoring in cancer chemotherapy","volume":"2","author":"Bach","year":"2010","journal-title":"Bioanalysis"},{"key":"10.1016\/j.cll.2026.07.007_bib2","unstructured":"National Comprehensive Cancer Network. Pediatric Acute Lymphoblastic Leukemia. Version 1.2026. National Comprehensive Cancer Network. Available at: NCCN Clinical Practice Guidelines. (Accessed 7 August 2026)."},{"issue":"3","key":"10.1016\/j.cll.2026.07.007_bib3","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3324\/haematol.2015.137380","article-title":"Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation","volume":"101","author":"Van Der Sluis","year":"2016","journal-title":"Haematologica"},{"issue":"13","key":"10.1016\/j.cll.2026.07.007_bib4","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1182\/blood-2013-10-534347","article-title":"A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia","volume":"123","author":"Tong","year":"2014","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.cll.2026.07.007_bib5","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/jnci\/91.23.2001","article-title":"Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-Methyltransferase gene locus","volume":"91","author":"Relling","year":"1999","journal-title":"JNCI Journal of the National Cancer Institute"},{"issue":"8","key":"10.1016\/j.cll.2026.07.007_bib6","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1056\/NEJM199802193380803","article-title":"Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia","volume":"338","author":"Evans","year":"1998","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.cll.2026.07.007_bib7","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1177\/1078155207081133","article-title":"Therapeutic drug monitoring of cancer chemotherapy","volume":"13","author":"Alnaim","year":"2007","journal-title":"J Oncol Pharm Pract"},{"issue":"9","key":"10.1016\/j.cll.2026.07.007_bib8","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2411680","article-title":"Blinatumomab in standard-risk B-Cell acute lymphoblastic leukemia in children","volume":"392","author":"Gupta","year":"2025","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.cll.2026.07.007_bib9","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1200\/JCO-25-01806","article-title":"Sustained benefit of blinatumomab in infants with KMT2A-rearranged ALL: long-term outcomes, toxicity, and pharmacokinetics","volume":"44","author":"Vieira Martins","year":"2026","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.cll.2026.07.007_bib10","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1634\/theoncologist.2017-0243","article-title":"Consensus guideline for use of glucarpidase in patients with high-dose methotrexate induced acute kidney injury and delayed methotrexate clearance","volume":"23","author":"Ramsey","year":"2018","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.cll.2026.07.007_bib11","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJMra052603","article-title":"Treatment of acute lymphoblastic leukemia","volume":"354","author":"Pui","year":"2006","journal-title":"N Engl J Med"},{"issue":"8 Pt 2","key":"10.1016\/j.cll.2026.07.007_bib12","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1093\/clinchem\/42.8.1322","article-title":"Concepts in use of high-dose methotrexate therapy","volume":"42","author":"Treon","year":"1996","journal-title":"Clin Chem"},{"issue":"8","key":"10.1016\/j.cll.2026.07.007_bib13","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1056\/NEJM198602203140803","article-title":"Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia","volume":"314","author":"Evans","year":"1986","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.cll.2026.07.007_bib14","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1200\/JCO.1988.6.5.797","article-title":"Effect of hydration on methotrexate plasma concentrations in children with acute lymphocytic leukemia","volume":"6","author":"Christensen","year":"1988","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.cll.2026.07.007_bib15","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1200\/JCO.1994.12.8.1667","article-title":"Patient characteristics associated with high-risk methotrexate concentrations and toxicity","volume":"12","author":"Relling","year":"1994","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.cll.2026.07.007_bib16","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","article-title":"Preventing and managing toxicities of high-dose methotrexate","volume":"21","author":"Howard","year":"2016","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.cll.2026.07.007_bib17","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/cpt.1957","article-title":"MTXPK.org: a clinical decision support tool evaluating high-dose methotrexate pharmacokinetics to inform post-infusion care and use of glucarpidase","volume":"108","author":"Taylor","year":"2020","journal-title":"Clin Pharmacol Therapeut"},{"issue":"11","key":"10.1016\/j.cll.2026.07.007_bib18","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1111\/cts.13600","article-title":"Clinical covariates that improve the description of high dose methotrexate pharmacokinetics in a diverse population to inform MTXPK.org","volume":"16","author":"Taylor","year":"2023","journal-title":"Clin Transl Sci"},{"issue":"2","key":"10.1016\/j.cll.2026.07.007_bib19","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00280-013-2206-x","article-title":"Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments","volume":"72","author":"Pauley","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1016\/j.cll.2026.07.007_bib20","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00280-018-3733-2","article-title":"A prospective study of a simple algorithm to individually dose high-dose methotrexate for children with leukemia at risk for methotrexate toxicities","volume":"83","author":"Foster","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.cll.2026.07.007_bib21","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/MPH.0000000000000696","article-title":"Using a bedside algorithm to individually dose high-dose methotrexate for patients at risk for toxicity","volume":"39","author":"Foster","year":"2017","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.cll.2026.07.007_bib22","article-title":"Intrainfusion drug monitoring and algorithm-based dose adjustments for children with ALL receiving high-dose methotrexate are feasible and safe in Costa Rica, a Low- and middle-income country","volume":"11","author":"Acevedo","year":"2025","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.cll.2026.07.007_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.941182","article-title":"Optimizing thiopurine therapy in children with acute lymphoblastic leukemia: a promising \u201cMINT\u201d sequencing strategy and therapeutic \u201cDNA-TG\u201d monitoring","volume":"13","author":"Guo","year":"2022","journal-title":"Front Pharmacol"},{"issue":"9","key":"10.1016\/j.cll.2026.07.007_bib24","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/FPC.0b013e328334338f","article-title":"Thiopurine pathway","volume":"20","author":"Zaza","year":"2010","journal-title":"Pharmacogenet Genom"},{"issue":"9018","key":"10.1016\/j.cll.2026.07.007_bib25","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/S0140-6736(96)91615-3","article-title":"Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12 000 randomised children","volume":"347","author":"Group","year":"1996","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.cll.2026.07.007_bib26","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1038\/s41375-022-01591-4","article-title":"Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations","volume":"36","author":"Toksvang","year":"2022","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.cll.2026.07.007_bib27","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1200\/JCO.2011.38.9924","article-title":"Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-hispanic white children with acute lymphoblastic leukemia: a report from the children\u2019s oncology group","volume":"30","author":"Bhatia","year":"2012","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.cll.2026.07.007_bib28","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1182\/blood-2014-01-552166","article-title":"6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a children\u2019s oncology group study","volume":"124","author":"Bhatia","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.cll.2026.07.007_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.1304","article-title":"Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update","volume":"105","author":"Relling","year":"2019","journal-title":"Clin Pharmacol Therapeut"},{"issue":"1","key":"10.1016\/j.cll.2026.07.007_bib30","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41431-025-01986-8","article-title":"Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between TPMT\/NUDT15 and thiopurines","volume":"34","author":"Coenen","year":"2026","journal-title":"Eur J Hum Genet"},{"issue":"4","key":"10.1016\/j.cll.2026.07.007_bib31","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1365-2125.2010.03867.x","article-title":"Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy","volume":"71","author":"Adam de Beaumais","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.cll.2026.07.007_bib32","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/pbc.24913","article-title":"Use of allopurinol in children with acute lymphoblastic leukemia to reduce skewed thiopurine metabolism","volume":"61","author":"Brackett","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"10.1016\/j.cll.2026.07.007_bib33","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1080\/10428194.2019.1702183","article-title":"Use of allopurinol to reduce hepatotoxicity from 6-mercaptopurine (6-MP) in patients with acute lymphoblastic leukemia (ALL)","volume":"61","author":"Stuckert","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.cll.2026.07.007_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.01129","article-title":"Use of allopurinol to mitigate 6-Mercaptopurine associated gastrointestinal toxicity in acute lymphoblastic leukemia","volume":"10","author":"Conneely","year":"2020","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.cll.2026.07.007_bib35","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/ibd.21494","article-title":"Optimizing thiopurine therapy in inflammatory bowel disease","volume":"17","author":"Chevaux","year":"2011","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"10.1016\/j.cll.2026.07.007_bib36","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00007691-200404000-00024","article-title":"Analytic aspects of monitoring therapy with thiopurine medications","volume":"26","author":"Armstrong","year":"2004","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.cll.2026.07.007_bib37","article-title":"LC\u2013MS\/MS method for measurement of thiopurine nucleotides (TN) in erythrocytes and association of TN concentrations with TPMT enzyme activity","volume":"13doi","author":"Bajaj","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cll.2026.07.007_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2025.124872","article-title":"An optimized LC-ESI-MS\/MS assay for erythrocyte 6-TG and 6-MMPD: addressing critical methodological considerations for thiopurine metabolite monitoring","volume":"1269","author":"Chu","year":"2026","journal-title":"J Chromatogr B"},{"issue":"5","key":"10.1016\/j.cll.2026.07.007_bib39","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1097\/01.ftd.0000169061.52715.3e","article-title":"Thiopurine therapies: problems, complexities, and progress with monitoring thioguanine nuc","volume":"27","author":"Duley","year":"2005","journal-title":"Ther Drug Monit"},{"issue":"4","key":"10.1016\/j.cll.2026.07.007_bib40","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/bcp.12226","article-title":"Implementation of TPMT testing","volume":"77","author":"Lennard","year":"2014","journal-title":"Br J Clin Pharmacol"},{"issue":"16\u201318","key":"10.1016\/j.cll.2026.07.007_bib41","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1080\/14622416.2025.2463866","article-title":"TPMT and NUDT15 genotyping, TPMT enzyme activity and metabolite determination for thiopurines therapy: a reference laboratory experience","volume":"25","author":"Shaaban","year":"2024","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.cll.2026.07.007_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.902117","article-title":"Current use of asparaginase in acute lymphoblastic leukemia\/lymphoblastic lymphoma","volume":"10","author":"Maese","year":"2022","journal-title":"Front Pediatr"},{"issue":"17","key":"10.1016\/j.cll.2026.07.007_bib43","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1200\/JCO.19.03024","article-title":"Impact of asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: a report from the children\u2019s oncology group","volume":"38","author":"Gupta","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.cll.2026.07.007_bib44","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/FTD.0000000000000030","article-title":"Immediate cooling does not prevent the ex vivo hydrolysis of L-asparagine by asparaginase","volume":"36","author":"Lanvers-Kaminsky","year":"2014","journal-title":"Ther Drug Monit"},{"issue":"24","key":"10.1016\/j.cll.2026.07.007_bib45","first-page":"6568","article-title":"Measurement of serum L-asparagine in the presence of L-asparaginase requires the presence of an L-asparaginase inhibitor","volume":"51","author":"Asselin","year":"1991","journal-title":"Cancer Res"},{"issue":"11 Pt 1","key":"10.1016\/j.cll.2026.07.007_bib46","first-page":"4554","article-title":"L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans","volume":"41","author":"R","year":"1981","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.cll.2026.07.007_bib47","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/0959-8049(96)00131-1","article-title":"Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations","volume":"32","author":"Boos","year":"1996","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.cll.2026.07.007_bib48","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0003-2697(02)00232-4","article-title":"Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of L-asparaginase in human serum","volume":"309","author":"Lanvers","year":"2002","journal-title":"Anal Biochem"},{"issue":"7","key":"10.1016\/j.cll.2026.07.007_bib49","first-page":"478","article-title":"High-throughput asparaginase activity assay in serum of children with leukemia","volume":"6","author":"Fernandez","year":"2013","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.cll.2026.07.007_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2024.116243","article-title":"Improved HPLC method with automated pre-column sample derivatisation for serum pegylated L-asparaginase activity measurement in paediatric acute lymphoblastic leukaemia patients","volume":"247","author":"Tan","year":"2024","journal-title":"J Pharmaceut Biomed Anal"},{"key":"10.1016\/j.cll.2026.07.007_bib51","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2147\/BLCTT.S342052","article-title":"Asparaginase in the treatment of acute lymphoblastic leukemia in adults: current evidence and place in therapy","volume":"12","author":"Juluri","year":"2022","journal-title":"Blood Lymphatic Cancer Targets Ther"},{"issue":"6","key":"10.1016\/j.cll.2026.07.007_bib52","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1016\/S1470-2045(16)30035-3","article-title":"Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus","volume":"17","author":"Schmiegelow","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cll.2026.07.007_bib53","article-title":"Mechanisms and signaling pathways of tyrosine kinase inhibitor resistance in chronic myeloid leukemia: a comprehensive review","volume":"24","author":"Lahmouad","year":"2025","journal-title":"Leuk Res Rep"},{"issue":"12","key":"10.1016\/j.cll.2026.07.007_bib54","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.3390\/ijms21124469","article-title":"Bcr-Abl tyrosine kinase inhibitors in the treatment of pediatric CML","volume":"21","author":"Carofiglio","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.cll.2026.07.007_bib55","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1182\/blood-2010-07-294330","article-title":"Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib","volume":"117","author":"Haouala","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cll.2026.07.007_bib56","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ejca.2021.08.033","article-title":"Therapeutic drug monitoring in oncology: International association of therapeutic drug monitoring and clinical toxicology consensus guidelines for imatinib therapy","volume":"157","author":"Clarke","year":"2021","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.cll.2026.07.007_bib57","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1111\/bjh.20047","article-title":"Therapeutic drug monitoring of imatinib in paediatric chronic myeloid leukaemia: data from a real-world setting","volume":"206","author":"Suttorp","year":"2025","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cll.2026.07.007_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.632231","article-title":"Dasatinib in the management of pediatric patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"11","author":"Cerchione","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.cll.2026.07.007_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.797881","article-title":"Therapeutic drug monitoring and individualized medicine of dasatinib: focus on clinical pharmacokinetics and pharmacodynamics","volume":"12","author":"He","year":"2021","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.cll.2026.07.007_bib60","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/cpt.787","article-title":"Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology","volume":"102","author":"Verheijen","year":"2017","journal-title":"Clin Pharmacol Therapeut"},{"issue":"5","key":"10.1016\/j.cll.2026.07.007_bib61","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1515\/cclm-2015-0578","article-title":"Head to head evaluation of the analytical performance of two commercial methotrexate immunoassays and comparison with liquid chromatography-mass spectrometry and the former fluorescence polarization immunoassay","volume":"54","author":"Gunther","year":"2016","journal-title":"Clin Chem Lab Med"},{"issue":"Supplement_1","key":"10.1016\/j.cll.2026.07.007_bib62","doi-asserted-by":"crossref","DOI":"10.1093\/clinchem\/hvad097.650","article-title":"B-331 homogeneous enzyme immunoassay for the quantitative determination of methotrexate","volume":"69","author":"Nguyen-Choi","year":"2023","journal-title":"Clin Chem"},{"issue":"2","key":"10.1016\/j.cll.2026.07.007_bib63","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/jalm\/jfaf189","article-title":"Multi-site validation of a newly FDA-cleared automated methotrexate immunoassay for therapeutic drug monitoring","volume":"11","author":"Maher","year":"2026","journal-title":"J Appl Lab Med"},{"issue":"2","key":"10.1016\/j.cll.2026.07.007_bib64","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/FTD.0b013e31824b93a5","article-title":"Improved sensitivity for methotrexate analysis using enzyme multiplied immunoassay technique on the Siemens Viva-E instrument","volume":"34","author":"Borgman","year":"2012","journal-title":"Ther Drug Monit"},{"issue":"11","key":"10.1016\/j.cll.2026.07.007_bib65","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1515\/cclm-2022-1001","article-title":"An isotope dilution-liquid chromatography-tandem mass spectrometry (ID-LC-MS\/MS)-based candidate reference measurement procedure (RMP) for the quantification of methotrexate in human serum and plasma","volume":"61","author":"Engel","year":"2023","journal-title":"Clin Chem Lab Med"}],"container-title":["Clinics in Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271226000776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271226000776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:40:30Z","timestamp":1792593630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272271226000776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S0272271226000776"],"URL":"https:\/\/doi.org\/10.1016\/j.cll.2026.07.007","relation":{},"ISSN":["0272-2712"],"issn-type":[{"value":"0272-2712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of Therapeutic Drug Monitoring in the Treatment of Childhood Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinics in Laboratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cll.2026.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}